Validation of Gene Expression Markers of Renal Allograft Functional Decline

Overview

About this study

Researchers would like to see if it is possible to predict which transplanted kidneys will do better long term based on the gene expression within a kidney biopsy one year after transplant. Gene expression profiling is used to study the activity of genes. Each gene has an "on/off" switch that controls how they are expressed in a cell, as well as a "volume control" that increases or decreases the level of expression of a particular gene as necessary. Researchers want to see if the presence and abundance of certain transcripts in a kidney biopsy at one year after transplant can predict which kidneys will have reduced function over time.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Adult (≥18 years) conventional renal transplant recipient.
Patients who have given informed consent and are willing to comply with the protocol.

Exclusion Criteria:

ABO incompatible kidney transplants.
Positive crossmatch kidney transplants (T cell crossmatch >100, B flow cytometric crossmatch >150).
Simultaneous kidney and extra-renal organ transplants including pancreas, liver, heart, lung, etc. Subjects who had previous extra renal transplants may be included in the study.
Patients taking chronic anticoagulation, which includes Coumadin, Plavix and any type of heparin. Aspirin is acceptable but must be stopped 5 days prior to the renal biopsy.
An inability to have the 1-year renal biopsy performed within the acceptable protocol window (Months 11-14 [Days 301-420] post transplant).

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status	Contact
Rochester, Minn. Mayo Clinic principal investigator Mark Stegall, M.D.	Closed for enrollment	Contact information: Nong Braaten (507)538-9617 Braaten.Nong@mayo.edu
Scottsdale/Phoenix, Ariz. Mayo Clinic principal investigator Mark Stegall, M.D.	Closed for enrollment	Contact information: Angela Eyshou CCRP (480)342-3906 Eyshou.Angela@mayo.edu
Jacksonville, Fla. Mayo Clinic principal investigator Mark Stegall, M.D.	Closed for enrollment	Contact information: Dana Kontras D.N.P., M.S.N., R.N., C.C.R.C.

Mayo Clinic Location

Status

Contact

Rochester, Minn.

Mayo Clinic principal investigator

Mark Stegall, M.D.

Closed for enrollment

Contact information:

Nong Braaten

(507)538-9617

Braaten.Nong@mayo.edu

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Mark Stegall, M.D.

Closed for enrollment

Contact information:

Angela Eyshou CCRP

(480)342-3906

Eyshou.Angela@mayo.edu

Jacksonville, Fla.

Mayo Clinic principal investigator

Mark Stegall, M.D.

Closed for enrollment

Contact information:

Dana Kontras D.N.P., M.S.N., R.N., C.C.R.C.

More information

Publications

Publications are currently not available

Clinical Trials